The U.S. Food and Drug Administration (FDA) confirmed it is taking action to supply the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available in the USA and globally.
On June 11, 2021, the FDA announced that it is authorizing for use under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, two batches of vaccine drug substance previously manufactured at the Emergent BioSolutions facility in Baltimore, MD.
J&J COVID-19 Vaccines Authorized for Worldwide Deployment
MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections
Incidence was higher in Black, Hispanic or Latino, and Asian or Pacific Islander persons versus Whites
Hemodialysis Patients Have Antibody Response to COVID-19 Vaccine
But few kidney transplant recipients develop anti-spike SARS-CoV-2 antibodies after second mRNA vaccine dose
Heart Attack, Stroke Care Rebound During Pandemic
Biggest, latest COVID-19 surge did not show declines in stroke, heart attack presentation as seen early in the pandemic
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of June 7 to 11, 2021. This …
CDC Issues Alert About Respiratory Syncytial Virus Spread in Southern U.S.
Agency is encouraging broader testing for RSV among patients presenting with acute respiratory illness who test negative for COVID-19
FDA: J&J Contaminated COVID-19 Vaccine Doses Must Be Discarded
Plant responsible for contamination has been closed for two months; the FDA has not yet decided whether it can reopen
CDC Calls Emergency Meeting on Heart Inflammation Link to COVID-19 Vaccines
Agency has identified 226 reports so far that may meet its ‘working case definition’ of myocarditis and pericarditis